Literature DB >> 1605203

Concerning the role of X-inactivation and DNA methylation in fragile X syndrome.

B R Migeon1.   

Abstract

Elucidation of the role of DNA methylation in X chromosome inactivation along with recent studies of the fragile X mutation suggests that DNA methylation is likely to be a late event in the pathogenesis of the fragile X syndrome. Thus far, the evidence does not support suggestions that an impediment to X reactivation and failure to demethylate the inactive X in oocytes is responsible for silencing the fragile X. The role of DNA methylation is probably secondary to amplification of the CGG repeat to a critical size whether on active or inactive X. Further studies are needed to determine if late replication of the inactive X predisposes the locus on that chromosome to more extensive amplification.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1605203     DOI: 10.1002/ajmg.1320430145

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  4 in total

1.  Genome-wide analysis of aberrant methylation in human breast cancer cells using methyl-DNA immunoprecipitation combined with high-throughput sequencing.

Authors:  Yoshinao Ruike; Yukako Imanaka; Fumiaki Sato; Kazuharu Shimizu; Gozoh Tsujimoto
Journal:  BMC Genomics       Date:  2010-02-25       Impact factor: 3.969

Review 2.  Fragile X syndrome.

Authors:  A E Donnenfeld
Journal:  Indian J Pediatr       Date:  1998 Jul-Aug       Impact factor: 1.967

3.  Diagnosis of bladder cancer recurrence based on urinary levels of EOMES, HOXA9, POU4F2, TWIST1, VIM, and ZNF154 hypermethylation.

Authors:  Thomas Reinert; Michael Borre; Anders Christiansen; Gregers G Hermann; Torben F Ørntoft; Lars Dyrskjøt
Journal:  PLoS One       Date:  2012-10-03       Impact factor: 3.240

4.  Methylation markers for urine-based detection of bladder cancer: the next generation of urinary markers for diagnosis and surveillance of bladder cancer.

Authors:  Thomas Reinert
Journal:  Adv Urol       Date:  2012-06-18
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.